PROTECT YOUR DNA WITH QUANTUM TECHNOLOGY
Orgo-Life the new way to the future Advertising by AdpathwayA large systematic review and meta-analysis of four randomized controlled trials encompassing 511,890 participants has demonstrated that high-dose quadrivalent influenza vaccination provides superior clinical protection against cardio-respiratory and cardiovascular hospitalizations in adults aged 65 years and older when compared with standard-dose quadrivalent vaccination. Seasonal influenza has long been established as a primary cause of severe respiratory illness and mortality among older populations, but contemporary research increasingly highlights its role as an acute trigger for severe vascular decompensation, including myocardial infarction, stroke, and heart failure exacerbations. To evaluate whether delivering four times the standard antigen dose mitigates these severe clinical events, investigators pooled individual trial data from Denmark, Spain, and Finland spanning influenza seasons from 2019/2020 through 2024/2025.
The study protocol, registered prospectively in PROSPERO and carried out under PRISMA guidelines and the Cochrane Handbook for Systematic Reviews, established stringent inclusion parameters focusing strictly on randomized trials directly comparing high-dose quadrivalent inactivated influenza vaccine with standard-dose quadrivalent inactivated formulations. Older adults experience diminished immune responses to routine immunization due to age-related immunosenescence, presenting a biological rationale for evaluating the high-dose formulation containing 60 micrograms of hemagglutinin per strain against the conventional 15 micrograms per strain. By excluding earlier trivalent preparations and mixed-strain trials that introduced confounding through vaccine mismatch, the researchers isolated the direct protective effects of antigen escalation on serious cardiopulmonary events.
Across the four evaluated trials—encompassing landmark pragmatic studies such as DANFLU-1, DANFLU-2, GALFLU, and FinFluHD—a total of 511,890 older individuals were analyzed, with treatment allocation divided almost evenly between the high-dose cohort at 50.03 percent and the standard-dose cohort at 49.97 percent. The mean participant age was 73.2 years with a standard deviation of 5.4 years, women comprised 48.1 percent of the population, and 22.6 percent presented with documented cardiovascular disease at baseline. Follow-up across the included trials ranged from 3 to 8 months, reflecting seasonal coverage across varied healthcare systems and registry environments in Northern and Southern Europe.
The primary pairwise meta-analyses, conducted using random-effects models regardless of heterogeneity, revealed that recipients of the high-dose vaccine experienced a statistically significant 7 percent reduction in the odds of cardio-respiratory hospitalization (odds ratio 0.93, 95% confidence interval 0.90 to 0.97, P = 0.0004) and a corresponding 7 percent reduction in cardiovascular hospitalization (odds ratio 0.93, 95% confidence interval 0.89 to 0.98, P = 0.009). For both endpoints, between-study heterogeneity was absent with an I-squared value of 0 percent. In contrast, the analysis identified no statistically significant reduction in overall respiratory hospitalization (odds ratio 0.90, 95% confidence interval 0.80 to 1.01, P = 0.072), which demonstrated moderate statistical heterogeneity at an I-squared of 50.5 percent.
When absolute risk reductions were calculated from pooled crude event rates, the absolute risk reduction for cardio-respiratory hospitalization was 0.00141, yielding a number needed to treat of 708 older adults (95% confidence interval 456 to 1,580) across a single influenza season to avert one hospitalization. For cardiovascular hospitalization, the absolute risk reduction was 0.00080, corresponding to a number needed to treat of 1,256 (95% confidence interval 719 to 4,944). For respiratory hospitalization, the calculated number needed to treat was 1,516 with a confidence interval spanning 847 to 7,190. While absolute numbers appear modest on an individual scale, their clinical relevance is amplified substantially when immunization programs are deployed across millions of older adults.
Secondary respiratory outcomes highlighted a pronounced divergence between pathogen-specific diagnoses and broader pulmonary syndromes. High-dose vaccination yielded substantial and statistically significant protections against overall influenza hospitalization (odds ratio 0.61, 95% confidence interval 0.50 to 0.74, P < 0.0001) and laboratory-confirmed influenza hospitalization (odds ratio 0.69, 95% confidence interval 0.56 to 0.86, P = 0.0008), both exhibiting low heterogeneity. Conversely, high-dose vaccination did not demonstrate a statistically significant benefit against the composite endpoint of influenza or pneumonia hospitalization (odds ratio 0.82, 95% confidence interval 0.66 to 1.04, P = 0.097) or pneumonia hospitalization alone (odds ratio 0.98, 95% confidence interval 0.90 to 1.06, P = 0.59). The authors noted that diagnostic coding variability and competing bacterial or non-viral etiologies often dilute vaccine effect measurements in non-specific pneumonia categories.
Among discrete cardiovascular outcomes, the primary driver of cardiovascular protection was a statistically significant 20 percent decrease in heart failure hospitalizations (odds ratio 0.80, 95% confidence interval 0.69 to 0.94, P = 0.0050), showing completely homogeneous trial effects with an I-squared of 0 percent. Acute influenza infection is known to exacerbate heart failure via metabolic stress, fever-induced tachycardia, hypoxemia, and acute inflammatory myocardial depression. In contrast, ischemic and cerebrovascular outcomes showed no significant differences between vaccine groups, including major adverse cardiovascular events (odds ratio 0.95, 95% confidence interval 0.85 to 1.07, P = 0.394), myocardial infarction (odds ratio 1.04, 95% confidence interval 0.83 to 1.29, P = 0.753), stroke (odds ratio 0.95, 95% confidence interval 0.85 to 1.06, P = 0.374), and atrial fibrillation (odds ratio 0.96, 95% confidence interval 0.87 to 1.05, P = 0.383).
Prespecified subgroup analyses stratified by baseline cardiovascular disease status demonstrated that the relative risk reduction remained stable regardless of whether patients had pre-existing cardiovascular conditions. Although cardiovascular hospitalization reductions reached formal statistical significance only in the subgroup without baseline cardiovascular disease (odds ratio 0.91, 95% confidence interval 0.84 to 0.98) and not in the subgroup with baseline disease (odds ratio 0.94, 95% confidence interval 0.88 to 1.01), interaction testing confirmed no significant subgroup differences (P = 0.49). Interaction tests were likewise non-significant for cardio-respiratory (P = 0.83) and respiratory hospitalizations (P = 0.47). Subsequent exploratory meta-regression confirmed that trial-level baseline cardiovascular disease prevalence did not modify the treatment effect for any primary outcome.
Rigorous statistical verification through trial sequential analysis affirmed that the cumulative evidence for cardio-respiratory and cardiovascular hospitalizations crossed the trial sequential monitoring boundaries for benefit and exceeded the required information size, establishing that findings for these outcomes are firm and unlikely to be altered by future trials. For respiratory hospitalizations, however, the cumulative Z-curve remained within sequential boundaries and failed to meet the required information size, indicating that additional research is necessary to achieve conclusive statistical power. Using the GRADE framework, certainty of evidence was rated high for cardio-respiratory and cardiovascular disease hospitalizations, moderate for heart failure and influenza hospitalizations, and low for the composite of influenza or pneumonia hospitalization due to substantial heterogeneity.
Assessment of general clinical and safety endpoints revealed no significant differences between high-dose and standard-dose cohorts. High-dose vaccination was not associated with significant alterations in total all-cause hospitalization (odds ratio 0.97, 95% confidence interval 0.93 to 1.01, P = 0.12) or all-cause mortality (odds ratio 0.93, 95% confidence interval 0.77 to 1.11, P = 0.413). Reassuringly, safety profiles were comparable, with no significant differences observed in serious adverse events (odds ratio 0.98, 95% confidence interval 0.93 to 1.03, P = 0.419) or serious adverse reactions (odds ratio 0.49, 95% confidence interval 0.10 to 2.35, P = 0.371), indicating that the antigen enhancement provides cardiopulmonary protection without introducing a measurable safety penalty.
Study limitations noted by the authors include the small number of eligible randomized controlled trials despite the vast participant registry, the restriction of trial settings to high-income European healthcare infrastructures, and the open-label design of three included trials, though the reliance on objective registry-derived discharge codes minimized potential performance and detection bias. The relatively short seasonal follow-up periods of 3 to 8 months prevent conclusions regarding long-term clinical trajectories. Nevertheless, the authors concluded that these robust findings substantiate the preferential use of high-dose quadrivalent influenza vaccination among older adults, underscoring immunization as an integral component of comprehensive preventive cardiology.
Subject of Research: Comparative effectiveness of high-dose versus standard-dose quadrivalent influenza vaccines on cardiovascular and respiratory hospitalizations in older adults
Article Title: High-dose quadrivalent influenza vaccine in older adults with or without cardiovascular risk: a meta-analysis of randomized trials on 511,890 participants
Article References: Elgendy, M. S., Shubietah, A., Awashra, A., Rifai, M., Qwaider, M., Faheem, M. A., Abuwatfa, M. A., Ismayl, M., & Alqadi, M. (2026). High-dose quadrivalent influenza vaccine in older adults with or without cardiovascular risk: a meta-analysis of randomized trials on 511,890 participants. Immunity & Ageing, 23(1), Article 23. https://doi.org/10.1186/s12979-026-00571-x
Image Credits: AI Generated
DOI: 10.1186/s12979-026-00571-x
Keywords: influenza vaccine, high-dose quadrivalent vaccine, older adults, cardiovascular hospitalization, cardiorespiratory hospitalization, heart failure, randomized controlled trials, meta-analysis, immunosenescence, preventive cardiology, inactivated influenza vaccine, DANFLU-2, GALFLU, FinFluHD, trial sequential analysis, GRADE assessment


1 day ago
10




















English (US) ·
French (CA) ·